STOCK TITAN

CYAD - CYAD STOCK NEWS

Welcome to our dedicated page for CYAD news (Ticker: CYAD), a resource for investors and traders seeking the latest updates and insights on CYAD stock.

Celyad Oncology (symbol: CYAD) is a clinical-stage biopharmaceutical company founded in 2007. The company is renowned for its expertise in cell-based therapies, particularly in taking them from the initial research phase to Phase III clinical trials. Celyad boasts robust manufacturing and logistical infrastructure designed to support the development of complex cell-based products.

Celyad's business model is rooted in strategic partnerships with esteemed research institutions such as Dartmouth College. These collaborations are instrumental in advancing their innovative programs from bench research to commercial applications.

One of the company's major focus areas is immuno-oncology, where it is pioneering the development of natural killer receptor T-cells (NKR-T cells) aimed at treating cancer. This unique therapeutic approach has shown promise in targeting and potentially destroying a wide variety of tumor types, positioning Celyad at the forefront of cancer treatment innovation.

Listed on Euronext Brussels, Euronext Paris, and NASDAQ under the ticker symbol CYAD, Celyad continues to gain recognition for its groundbreaking work in the biotech industry. The financial condition of the company is robust, with ongoing projects that underscore its commitment to transforming cancer care. Recent achievements and current projects reflect a steadfast dedication to clinical excellence and innovation.

Rhea-AI Summary

Celyad Oncology, a clinical-stage biotechnology company focused on CAR T therapies for cancer, announced that Dr. David Gilham will participate in a panel discussion titled “Cell Therapies in the Next Decade” on July 14, 2021, at the William Blair Biotech Focus Conference. The event will be held virtually from July 14-15, and the management team will also engage in one-on-one investor meetings. A live audio webcast of the discussion will be available on the company’s website. Celyad continues to develop innovative cancer treatments through its extensive CAR T pipeline.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary

Celyad Oncology (CYAD) announced a capital increase of 306,800 new shares on June 30, 2021, through Lincoln Park Capital Fund, LLC and Jefferies LLC. This transaction raises the company's share capital to 53,912,224.33 EUR, now represented by 15,493,956 shares. The number of shares with single voting rights totals 13,125,931, while shares with double voting rights amount to 2,368,025. The total of diluted shares is 17,416,379. This disclosure complies with Belgian law regarding the transparency of major participations in trading companies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Celyad Oncology has announced promising preliminary data from the Phase 1 IMMUNICY-1 trial of CYAD-211 for treating relapsed/refractory multiple myeloma. The treatment was generally well-tolerated at the first two dose levels, with no Graft-versus-Host Disease and two partial responses among five evaluable patients. All patients showed cell engraftment after the second dose. Management plans to provide additional results in the second half of 2021 and highlighted the potential of shRNA technology for allogeneic CAR T therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary

Celyad Oncology announced a capital increase on May 31, 2021, issuing 182,000 new shares through its Open Market Sale Agreement with Jefferies LLC. This brings the company's total share capital to 52,844,560.33 EUR and increases total shares to 15,187,156. Following the increase, the total number of diluted shares stands at 17,114,912. This move follows Article 15 of Belgian law concerning the disclosure of major participations in publicly traded companies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Celyad Oncology SA, focused on CAR T therapies for cancer, will present at multiple conferences in June 2021. The presentations will be led by CEO Filippo Petti at events including the Jefferies Virtual Healthcare Conference, William Blair Annual Growth Stock Conference, and JMP Securities Life Sciences Conference. Notably, funding from Walloon Region has been received to support ongoing CAR T therapy programs. Celyad is developing both allogeneic and autologous CAR T candidates targeting hematological malignancies and solid tumors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Celyad Oncology SA (Euronext & Nasdaq: CYAD) received a transparency notification indicating that Victory Capital Management Inc. has crossed the 5% threshold in voting rights, holding 713,214 shares (4.11% of total shares) as of May 13, 2021. The notification reflects a downward crossing of the statutory threshold due to acquisition or disposal of voting securities. Victory Capital operates through multiple controlled undertakings, and it can exercise voting rights at its discretion.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

Celyad Oncology has announced positive initial results from the Phase 1 IMMUNICY-1 trial of its anti-BCMA CAR T candidate, CYAD-211, focused on relapsed/refractory multiple myeloma. The first dose-level cohort showed no Grade ≥ 3 treatment-related adverse events or Graft-versus-Host disease. Notably, a confirmed partial response was observed in one patient receiving a low dose of 30x106 cells. The trial aims to assess the safety and efficacy of CYAD-211, utilizing a non-gene editing technology that minimizes safety risks. Results will be presented at the upcoming EHA Virtual Congress 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences clinical trial
-
Rhea-AI Summary

Celyad Oncology has provided updates on its clinical trials and financial results for Q1 2021. The Phase 1 IMMUNICY-1 trial for CYAD-211, an allogeneic CAR T candidate, is ongoing with no safety issues reported. Additionally, the alloSHRINK trial for CYAD-101 is progressing, with preliminary data expected mid-2021. The company has appointed new key personnel and entered a $40 million equity purchase agreement with Lincoln Park Capital. As of March 31, 2021, Celyad had €12.2 million in cash, enough to fund operations until mid-2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Celyad Oncology (Euronext & Nasdaq: CYAD) announced on May 3, 2021, that Tolefi SA holds 2,295,701 shares with a double voting right, exceeding the 25% ownership threshold. This notification highlights Tolefi's increased influence in corporate decisions. Celyad Oncology is focused on developing CAR T cell therapies for cancer, including a pipeline of allogeneic and autologous candidates. The company has received funding from the Walloon Region in Belgium to advance its research initiatives.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

Celyad Oncology SA announced a double voting right for Tolefi SA’s shares effective May 3, 2021, increasing the total number of voting rights to 17,373,181. The company's total share capital amounts to €52,211,200.33, consisting of 12,637,131 shares with single voting rights and 2,368,025 shares with double voting rights. The disclosure is in line with the Belgian law regarding major participations in listed companies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none

FAQ

What is the market cap of CYAD (CYAD)?

The market cap of CYAD (CYAD) is approximately 14.2M.

What does Celyad Oncology specialize in?

Celyad Oncology specializes in developing cell-based therapies, particularly in immuno-oncology, using natural killer receptor T-cells (NKR-T cells) for cancer treatment.

When was Celyad Oncology founded?

Celyad Oncology was founded in 2007.

On which stock exchanges is Celyad listed?

Celyad is listed on Euronext Brussels, Euronext Paris, and NASDAQ.

What is the company's ticker symbol?

The ticker symbol for Celyad Oncology is CYAD.

Who are Celyad's key research partners?

Celyad collaborates with prominent research institutions such as Dartmouth College.

What are natural killer receptor T-cells (NKR-T cells)?

NKR-T cells are a type of cell therapy being developed by Celyad for targeting and destroying various tumor types in cancer treatment.

What is Celyad's business model?

Celyad's business model focuses on partnerships with research institutions to advance cell-based therapy programs from bench research to commercial applications.

What are some recent achievements of Celyad Oncology?

Celyad has recently made significant progress in its clinical programs in immuno-oncology and is advancing its NKR-T cell therapies through various stages of clinical trials.

What is the status of Celyad's financial condition?

Celyad maintains a robust financial condition, supporting ongoing projects and development efforts in cell-based cancer therapies.

How can I stay updated on Celyad's latest news?

You can stay updated on Celyad's latest news by following their official announcements and news releases on their website or financial news platforms.

CYAD

Nasdaq:CYAD

CYAD Rankings

CYAD Stock Data

14.24M
13.58M
0.05%
29.15%
0.58%
Biotechnology
Healthcare
Link
Belgium
Mont-Saint-Guibert